Definitive Contract 75N93018C00024
Award Date 9/20/18
Potential Completion Date 8/14/23
Potential Value $18M
Federal Agency
Awardee
Ultimate Awardee
Not listed Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Cost Plus Fixed Fee
Place of Performance
Australia
Solicitation Procedures
Basic Research
Number Of Offers Received
24
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $6,690,024.90 definitive, cost-no-fee contract to Vaxine PTY LTD, a for-profit organization located in Australia, for an Adjuvant Development Program. The contract, which has an ultimate completion date of February 10, 2025, was awarded on September 10, 2018 and does not have a set-aside designation. The contract aims to support the development of vaccine adjuvants, which are compounds that enhance the immune response to...
- The federal contract award HHSN272200800039C was a $8,394,390.00 definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Vaxine PTY LTD, a for-profit organization, on September 30, 2008. The contract is part of NIAID's Adjuvant Discovery Program and is for biomedical research services. It has a cost-no-fee pricing type and an ultimate completion date of September 29, 2013. The contract was not set aside for any specific business...
- This is a Cost Plus Fixed Fee contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Vaxxas PTY LTD, a for-profit company based in Australia, for the development of a Micro Array Patch (MAP) to deliver a vaccine against the H5N1 pandemic strain of influenza. The total ceiling value of the contract is $28,521,971.80 with a period of performance through December 30, 2026. No set-aside designation was used for this award. The University of Queensland, also...
- This is a $18,576,013.05 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to the Access To Advanced Health Institute (AAHI), a non-profit biotech research institute located in Seattle, Washington. The contract is for the development of vaccine candidates for biodefense, antimicrobial resistant infections, and emerging infectious diseases, under NIAID's Broad Agency Announcement (BAA) Research Area 001. AAHI...
- This is a cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services. The contract, with a ceiling value of $86,670,401.90, is for biomedical (advanced) products and services. The prime contractor is Janssen Vaccines & Prevention B.V., a foreign-owned for-profit organization. The contract does not have a set-aside designation and has an ultimate completion date...
- This is a $26,065,720.00 cost-plus-fixed-fee delivery order awarded to the International AIDS Vaccine Initiative (IAVI), a global non-profit organization, by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The contract is for the manufacture of human flu challenge material, which supports IAVI's mission to develop safe and effective preventive vaccines for infectious diseases. The award is part of IAVI's existing indefinite...
- This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the U.S. Department of Health and Human Services, to Sanofi Pasteur Biologics, LLC, a foreign-owned for-profit organization. The contract is for the development and testing of a modified vaccinia Ankara (MVA) vaccine, with a ceiling value of $12,667,339.96. The contract is a definitive, cost-plus-fixed-fee contract type, with a final completion date of January 8, 2007. The...
- This is a $7,833,415.85 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to GeoVax, Inc. for the development of a vaccine. The contract has an ultimate completion date of April 30, 2022 and is not designated as a set-aside. Based on the major program code, this contract is part of NIAID's "STAGE VACCINE DEVELOPMENT" efforts, though no further details about the specific vaccine being developed are...
- This is a definitive cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to AlphaVax Human Vaccines Inc. for R&D in physical science and exploratory development. The contract has a ceiling value of $16,660,130.44 and an ultimate completion date of August 14, 2012. It was initially awarded on September 26, 2003 and does not have a set-aside designation. AlphaVax Human Vaccines Inc. is a for-profit organization that...
- This federal contract award, valued at $16,731,358.00, was made by the National Institute of Allergy and Infectious Diseases (NIAID) to the Access To Advanced Health Institute (AAHI), a non-profit biotech research institute. The contract is for the continued development of vaccine candidates for biodefense, antimicrobial resistance, emerging infectious diseases, and respiratory pathogens. No set-aside designation was used. AAHI has subcontracted with several institutions, including Emory...